Effects of Common Analgesic Medications on Sleep: A Topical Review
Findings from a recent review highlight the impact of common analgesic medications on sleep patterns in people with chronic pain.
Make Early Alzheimer Disease Medications Accessible to All, Now
FDA-approved early Alzheimer medications should be covered by Medicare and other insurers and made immediately available to all those who will benefit.
FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions
Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.
COVID-19 Raises Risk of MACE up to 3 Years Later: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Updates Flublok Label with Safety Data for Pregnant Individuals
The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.
Beer, Cider Linked to Higher Risk of Gout: Daily Dose
Similar Rates of FIT Completion Support Initiating CRC Screening at Age 45: New Research
Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.
Why is Atopic Dermatitis Prevalence Rising? Dermatologist Mona Shahriari, MD, Parses the Trends
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
Exclusive Physician Survey Results on GLP-1 Receptor Agonists: The Hype Is Real
Three-quarters of primary care survey respondents prescribe GLP-1 RAs for weight loss and half get questions daily about the drugs. See all the results.
The Legacy of Vaccine Hesitancy: From COVID-19 to Flu
Vaccine hesitancy became a public health threat during the COVID-19 pandemic that lingers now and has affected uptake of other essential immunizations.
Pfizer-BioNTech COVID-19 Vaccine May Reduce Risk of Long COVID in Older Adults
IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.
Vertex Presents Phase 3 Data on Nonopioid Suzetrigine to Treat Acute Pain at Anesthesiologists' Annual Meeting
The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.
Novel PACAP-Targeted Antibody Reduces Monthly Migraine Days in Phase 2 HOPE Trial
A single 750 mg intravenous infusion of Lu AG09222 showed a 2-day difference in reducing monthly migraine day compared with placebo.
Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial
Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.
Atopic Dermatitis is Not "Just" Eczema: Disease Primer with Mona Shahriari, MD
Dermatology thought leader Mona Shihriari, MD, offers a brief overview of the inflammatory skin disease for primary care clinicians.
IDWeek 2024: Novavax Reports Positive Data for Novel Influenza and Flu-COVID-19 Combination Vaccines
IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.
IDWeek 2024: Merck’s 21-Valent Pneumococcal Vaccine Shows Positive Immune Responses in At-Risk Adults
V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.
7 Factors That Lead Americans to Skip Health Screening
Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.
Boost in CRC Screening after USPSTF Recommendation: Daily Dose
Elinzanetant Data from Bayer Feature Prominently at 19th World Congress on Menopause
Bayer announced 12 presentations focused on symptoms of menopause and effects of its investigational oral nonhormonal medication elinzanetant.
